Novo Vk
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 6869.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Biotech Laboratories (Pty) Ltd | Novo vk | 250 ml/5 ml | A0423 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Novo vk granules 250 ml/5 ML EACH 5,0 ml CONTAINS PHENOXYMETHYLPENICILLIN POTASSIUM A 318,8 mg | 250 ml/5 mlGranules | A0423 | Old Medicine | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Phenoxymethylpenicillin
- except when intended for the prophylaxis of rheumatic fever.
Consolidated Schedules 06 July 2026, line 7543
S3: Phenoxymethylpenicillin
- when intended for the prophylaxis of rheumatic fever.
Consolidated Schedules 06 July 2026, line 4118
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.